Inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease, affect an estimated 500,000 to 2 million people in the United States. Although there have been improvements in IBD treatments over time, many patients continue to have symptoms while taking conventional medications.
This study is testing the safety and effectiveness of an experimental therapy, bone marrow stromal cells (BMSC), for the treatment of moderate to severe inflammatory bowel diseases. BMSC are thought to repair tissue and reduce inflammation.
You may be eligible if you
Participants will receive four weekly BMSC infusions. Doctors will monitor participant responses to this therapy for three months.
The study is being conducted at the Warren Grant Magnuson Clinical Center (Building 10) at the National Institutes of Health (NIH) in Bethesda, Maryland. The NIH campus is accessible by car and public transportation.
There is no charge to participate in this research study. All study-related medical care and procedures are provided free of charge.
Yes, you may be compensated for your participation in the study. Transportation and other expenses may also be covered.
If you have questions or would like more information, contact:Patient Recruitment, NIH Clinical CenterToll free: 1-800-411-1222 (reference 13-I-0077)TTY: 1-866-411-1010 Se habla español.Email: firstname.lastname@example.org
To learn more about this study (trial ID NCT01851343), visit ClinicalTrials.gov.
Last Updated May 13, 2013
Last Reviewed February 13, 2015